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Purpose: Biologic evidence suggests that the Insulin-like growth factor (IGF)-family may be 
involved in the etiology of epithelial invasive ovarian cancer (EOC). However, prospective 
studies investigating the role of IGF-I in ovarian carcinogenesis have yielded conflicting 
results. 
Methods: We pooled and harmonized data from 6 case-control studies nested within the 
Ovarian Cancer Cohort Consortium to investigate the association between pre-diagnosis IGF-
I concentrations and subsequent risk of EOC. We evaluated IGF-I concentrations and risk of 
EOC overall and by tumor subtype (defined by histology, grade, stage) in 1,270 cases and 
2,907 matched controls. Multivariable conditional logistic regression models were used to 
calculate Odds Ratios (OR) and 95% Confidence Intervals (CI). 
Results: Doubling of IGF-I concentration was associated with significantly lower risk of 
overall EOC [ORlog2=0.82; CI: 0.72-0.93]. We observed no heterogeneity by tumor 
characteristics (e.g., histology, phet=0.62), menopausal status at blood collection (phet=0.79), 
or age at diagnosis (phet=0.60).  
Conclusions: These results suggest that IGF-I concentrations are inversely associated with 
EOC risk, independent of histological phenotype. Future prospective research should consider 
potential mechanisms for this association, including considering other members of the IGF-








Insulin-like growth factor (IGF) signalling has been implicated in the development of various 
epithelial cancers (e.g., breast and prostate), supported by evidence from in vitro and in vivo 
studies (as reviewed in: (1)). Data from mechanistic studies demonstrate a role for IGF-I in 
cellular proliferation, invasion, and angiogenesis of ovarian cancer cells (2, 3). Thus, a role 
for IGF-I in the development of epithelial invasive ovarian cancer (EOC) has been 
hypothesized.  
Prospective studies evaluating circulating concentrations of IGF-I and EOC risk have yielded 
inconclusive results (4-8). Emerging data support different etiologies for the main EOC 
histologic subtypes (e.g., serous, endometrioid, mucinous and clear cell tumors) (9), which 
can be categorized using the hypothesized dualistic model of ovarian carcinogenesis (i.e., type 
I, predominantly low grade serous and endometrioid histologies, as well as mucinous and 
clear cell tumors; and type II, predominantly higher grade serous and endometrioid) (10). 
However, in prior research evaluating circulating IGF-I and risk, EOC was predominantly 
investigated as a composite outcome due to limited power. To date, two studies evaluated 
differences in IGF-I associations across histologies and by developmental pathways with no 
clear heterogeneity (7, 8). 
In the present study, we pooled available data from 6 prospective cohort studies within the 
Ovarian Cancer Cohort Consortium (OC3) to investigate the association between pre-
diagnosis IGF-I and EOC risk among 1,270 invasive EOC cases and 2,907 matched controls. 
We investigated overall EOC risk, as well as heterogeneity by EOC subtypes (e.g., histology, 






Materials and Methods 
Study populations  
The OC3 has been described previously (9). For this investigation, eligible cohorts were 
required to have data on a defined set of a priori selected covariates (e.g., menopausal status 
at blood donation, oral contraceptive use at blood donation, parity) and pre-diagnosis 
measurements of circulating IGF-I. Data from the following OC3 studies were included in the 
current study: “Give Us a Clue to Cancer and Heart Disease” (CLUE II), the European 
Prospective Investigation into Cancer and Nutrition (EPIC) (7), the Harvard Women’s Health 
Study (WHS) (5), and the Nurses’ Health Studies (NHS and NHSII) (5). In addition to the 
OC3 cohorts, the Finnish Maternity Cohort (FMC) (8), a cohort of women pregnant at blood 
collection, contributed data to this investigation (for additional information on contributing 
cohorts, see Table S1). Available biomarker and questionnaire data from each cohort were 
centrally collated and harmonized.  
Ascertainment of cases 
Eligible cases included women diagnosed with incident epithelial invasive ovarian cancer 
(International Classification of Disease (ICD) codes: ICD9 codes 183 and 158; ICD10 codes 
C56) ascertained by self-report with medical record confirmation and/or linkage to cancer 
registries. Cases were individually matched to two or three controls on age, date, menopausal 
status and day or phase of menstrual cycle in premenopausal women, with exception of the 
FMC, which was restricted to currently pregnant women. Cases and controls in the FMC were 
matched on age and date at blood collection and parity at blood collection and diagnosis (or 
reference date for controls) (Table S1). Histologic classification was as follows: 50% of 
tumors were of serous histology (n=630), 13% endometrioid (n=163), 15% mucinous 
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(n=186), 4% clear cell (n=57) and 18% other (including “not otherwise specified” (NOS), 
malignant neoplasms, carcinoma, mixed Mullerian, mixed mesodermal or malignant Brenner 
tumors; n=234). The majority of cases had data on stage at diagnosis (n=1,044; 82%). 
Information on grade was available for 34% of the cases (missing for all FMC cases). Well-
differentiated tumors (i.e., grade 1) were classified as “low grade”, whereas moderately, 
poorly, and undifferentiated tumors (i.e., grades 2-4) were classified as “high grade”; well 
differentiated tumors had a district risk factor profile relative to moderately and poorly 
differentiated tumors in a previous study in the OC3, whereas moderately and poorly 
differentiated tumors clustered together (9). Data on histology and grade were used to classify 
tumors into developmental pathways. Low-grade serous and endometrioid, and all mucinous 
and clear cell cases were classified as Type I (49%, n=277); high-grade serous and 
endometrioid were classified as type II (51%, n=284) (10). Mucinous and clear cell cases 
from the FMC were characterized as Type I; however, all serous and endometrioid tumors 
from the FMC were excluded from Type I/Type II analyses given no data on grade were 
available. After excluding participants from FMC, we observed a type I / type II distribution 
as expected from the literature (type I: 28% vs. type II: 72%) (10). 
Laboratory methods 
Case-control sets from all cohorts were measured in the same batch and technicians 
performing the assays were blinded to case-control status and quality control samples. With 
the exception of EPIC and the FMC, which used serum, IGF-I was measured in plasma 
samples (Table S2). All studies, with exception of the FMC, used an enzyme-linked 
immunosorbent assay (ELISA); the FMC used a chemiluminescent immunoradiometric assay. 
Coefficients of variation ranged from 2% (NHS, NHSII, WHS) to 14.6% (FMC). To account 
for differences in study-specific mean concentrations and a different case-control ratio 
between studies (1:2 vs. 1:3), IGF-I concentrations were standardized based on the cohort-
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specific mean concentrations in controls (i.e., for each cohort, standardized concentration = 
original concentration – mean concentration in controls). 
 
Statistical analyses 
Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence 
intervals (CI). The association between IGF-I concentrations and EOC risk was evaluated on 
the log2-transformed continuous scale and in tertiles; quintiles were evaluated in a secondary 
analysis. Quantiles were defined based on the distribution in controls. Results from models 
considering study-specific quantiles vs. across-study quantiles based on the standardized IGF-
I concentrations were similar. Therefore, only results from across-study quantiles are 
presented. In order to account for potential differences in assay distribution between cohorts, a 
continuous probit score was used to test for trend across tertiles (generating a rank for each 
participant in each cohort by hormone concentration). Multivariable models were adjusted for 
parity (never, ever) and OC use ((never, ever, missing (48%); missing excluding FMC 
(0.3%)). We evaluated the impact of adjustment for body mass index (BMI; kg/m2) among the 
subset of the study population with this data available (686 cases and 1,442 controls). 
Statistical analyses were conducted using a two-stage approach. First, the log2 relative risks 
were calculated within each cohort and pooled using DerSimonian and Laird random effects 
meta-analysis models (11). Heterogeneity between cohort-specific effect estimates was tested 
by DerSimonian and Lairds Q statistic (11). Second, effect estimates based on pooled 
individual participant data were calculated. We observed no significant between-study 
heterogeneity in the meta-analysis, therefore, we present results based on the pooled 
participant data.  
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The assumption of linearity was tested using restricted cubic splines; no significant deviations 
from linearity were observed (data not shown). Statistical heterogeneity of associations across 
subtypes was assessed via a likelihood ratio test comparing a model allowing the association 
for the risk factor of interest to vary by subtype versus one assuming the same association 
across subtypes using polytomous conditional logistic regression (12). We evaluated 
heterogeneity by menopausal status at blood collection and age at diagnosis by including a 
multiplicative interaction term in the models and evaluating the Wald p value. The FMC 
(pregnant at blood collection) was excluded in a sensitivity analysis. Given the potential 
influence of IGF-I in early phases of carcinogenesis we evaluated risk associations excluding 
women diagnosed within 2 years after blood donation.  
SAS Statistical Software, version 9.3 (SAS Institute, Cary NC, USA) was used for all 
statistical analyses. P-values<0.05 were considered as statistically significant; all statistical 
tests and p-values were two-sided.  
Results 
In total, 1,270 cases and 2,907 matched controls were included; the number of cases and 
controls contributed from each of the participating studies ranged from 15 cases / 44 controls 
(NHS II) up to 575 cases / 1,427 controls (FMC) (Table 1). Women who were 
postmenopausal at blood collection accounted for 42% of the cases and 39% of the controls, 
and the majority of women (91% cases, 95% controls) were parous. The median duration of 
follow-up was 9.1 (SD: 6.1) years among incident cancer cases, ranging from 2.7 (SD: 1.9) 
years for NHS II to 12.3 (SD: 6.8) years for the FMC. Overall, mean age at diagnosis was 
54.6 (SD: 12.5) years with youngest cases in FMC (mean: 44.7 (SD: 8.1) years) and oldest 
cases in CLUE II (mean: 67.4 (SD: 13.0) years) (Table S3).  
Higher IGF-I concentrations were associated with lower EOC risk (all cases: ORlog2=0.82; 
[0.72-0.93]; Table 2). The ORs from analyses considering extreme tertiles vs. quintiles were 
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similar (Tertile 3 vs. 1, OR=0.75 [0.62-0.90]; Quintile 5 vs. 1, OR=0.74 [0.59-0.93]). We 
observed no between-study heterogeneity (phet=0.81; Figure 1), and results from the meta-
analysis were comparable to those of the pooled analysis (ORlog2=0.82 [0.73-0.94]). The 
association between IGF and EOC did not differ significantly across histological subtypes 
(phet=0.62) or for Type I vs. Type II disease (phet=0.67). We observed no significant 
heterogeneity by disease stage at diagnosis (local disease: ORlog2: 0.79 [0.59-1.06]; 
regional/metastatic disease, ORlog2: 0.84 [0.71-0.98]; phet: 0.79) or tumor grade (low grade: 
ORlog2: 1.25 [0.52-3.03]; high grade: ORlog2: 0.82 [0.63-1.07]; phet: 0.43); however, the 
number of low grade tumors was limited (n=49).  
Additional adjustment for BMI did not impact the associations (e.g., overall EOC among 
women with data on BMI: without adjusting for BMI: ORlog2: 0.89; [0.78-1.03] vs. adjusting 
for BMI ORlog2: 0.91; [0.79-1.04]). Results were similar by menopausal status at blood 
collection (phet=0.79) and age at diagnosis (phet=0.60). Exclusion of women from the FMC 
(after exclusion, ORlog2: 0.81 [0.67-0.98]) or women diagnosed within 2 years after blood 
donation (after exclusion, ORlog2: 0.86 [0.75-0.98] did not impact the results.  
Discussion 
We present the largest and most comprehensive study to date on the relationship between pre-
diagnosis IGF-I and risk of EOC, including 1,270 cases and 2,907 matched controls. In this 
collaborative re-analysis of 6 nested case-control studies, we observed an 18% risk reduction 
for overall EOC risk with a doubling of IGF-I concentration. We observed no heterogeneity 
between histological subtypes or by other tumor characteristics (e.g., stage, grade, type I/II).  
To date, 5 published prospective studies (n cases, range: 132 to 1,052), all of which are 
included in this pooled analysis, have addressed the association between IGF-I and EOC risk 
(4-8). Two of these investigations reported inverse associations overall (7, 8), whereas the 
others observed significant associations only in subgroups defined by age at diagnosis (4-6). 
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In the current study, we observed an inverse association between IGF-I and EOC risk overall, 
with no heterogeneity by age at diagnosis. To date, data on the role of IGF-I in the 
development of different EOC subtypes are sparse and generally did not support a 
heterogeneous association (7, 8). Consistent with those findings, we observed no 
heterogeneity by EOC subtype in this pooled re-analysis. 
IGF-I has well established mitogenic and anti-apoptotic properties (as reviewed in (1)), which 
are believed to underlie its association with a number of epithelial cancers. We therefore 
hypothesized a positive association between IGF-I and EOC risk. The observed inverse 
association is not in line with this hypothesis. The biological pathways underlying the inverse 
association observed in this study remain to be fully elucidated. One potential explanation for 
the observed inverse association may be the anti-inflammatory effects of IGF-I (13). Serum 
IGF-I is inversely correlated with C-reactive protein [CRP; (14)]. Recent nested case-control 
studies have shown a consistent positive association between high CRP concentrations (CRP 
> 10 mg/L) and subsequent risk of EOC (15-19) , although we were unable to adjust for CRP 
levels in this analysis. Clearly, additional research is needed to understand the potential 
biological mechanisms underlying the apparent inverse association between IGF-I and EOC 
risk.  
Given the large sample size, our study was powered to investigate risk associations overall, as 
well as for less common tumors (e.g., mucinous) and by the dualistic model of ovarian 
carcinogenesis. However, our study also has limitations. Data on tumor characteristics (e.g., 
missing data on grade: 66%, type I / type II: 56%) and potential confounders (e.g., BMI: 49%) 
was incomplete for some subgroup and sensitivity analyses. A general limitation of pooled 
analyses is between-cohort differences in data on covariates, biospecimen collection, and 
laboratory methods. Data from each cohort were centrally compiled and harmonized, and 
differences in absolute biomarker concentrations were addressed through (I) standardizing of 
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hormone measurement using study-specific mean concentrations and (II) using study-specific 
tertiles. IGF-I standardization was carried out under the assumption that between-study 
differences in IGF-I concentrations were due to differences in collection and/or laboratory 
methods, and not due to true underlying differences in concentrations between cohorts. 
Results were similar in analyses using meta-analysis and calculating OR from the pooling of 
individual data and we did not observe between-study heterogeneity. Limited covariate data 
were available for statistical adjustment. However, data from previous studies included in our 
pooled analysis do not suggest strong confounding of the association between IGF-I and EOC 
by lifestyle or reproductive factors (5, 7). Further, we included a cohort of women pregnant at 
blood collection (FMC) in this study. IGF-I concentrations decrease in early pregnancy, 
relative to pre-conception concentrations, with a subsequent increase in concentrations in 
mid-to late pregnancy until delivery (20). FMC blood samples were collected at a mean 10.4 
(controls) – 10.7 (cases) weeks gestation. Pre- and early pregnancy concentrations are 
modestly correlated (8 weeks gestation: r = 0.32; 16 weeks gestation: r = 0.15) (20).We 
excluded the FMC in sensitivity analyses, and observed similar results. An additional 
limitation is the quantification of circulation IGF-I in a single blood sample. However, the 
stability of IGF-I measurements over a 5 year period and its utility as epidemiologic 
biomarker has been shown previously (intra-class coefficient of variation: 0.74 (95% CI, 
0.55–0.93)) (21). Finally, IGF signaling is exceptionally complex as the distinct members of 
the IGF-family activate different downstream signaling pathways. This investigation only 
evaluated one member of the IGF-I family and EOC risk. Finally, it is unclear if circulating 
measures of IGF-I are related to exposure in the peritoneal cavity. 
In conclusion, our investigation does not support the hypothesis that elevated IGF-I 
concentrations increase risk of EOC overall or for specific disease subtypes. In contrast, in 
this large, pooled analysis, we observed a significant inverse association and no heterogeneity 
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by subtype. To more fully characterize the function of the IGF-pathway in ovarian 
carcinogenesis future investigations should consider other growth factors and binding proteins 
(e.g., IGF-II or Insulin-like factor III, IGFBP2, IGFBP3). 
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Table 1. Case and control characteristics by cohort in pooled analysis of prospective data on circulating IGF-I and EOC risk: the Ovarian Cancer Cohort Consortium (OC3)  











Clue II ≠ Case 46 60.8 (13.0) 19 20 85 26.3 (5.8) 
 ≠ Control 90 60.9 (12.9) 13 13 86 25.3 (4.7) 
EPIC Ose et al. 2015 Case 450 55.9 (8.5) 17 37 77 26.8 (4.9) 
  Control 864 55.9 (8.6) 12 45 77 26.3 (4.8) 
FMC Schock et al. 2015 Case 575 32.5 (4.8) 0 ≠≠ 0 ≠≠ 
  Control 1,427 32.5 (4.7) 0 ≠≠ 0 ≠≠ 
NHS Tworoger et al. 2007 Case 121 57.9 (6.5) 8 41 80 24.8 (4.8) 
  Control 360 57.8 (6.5) 4 47 80 24.7 (4.0) 
NHS II Tworoger et al. 2007 Case 15 46.1 (4.4) 20 93 20 29.6 (9.8) 
  Control 44 45.8 (4.2) 23 86 18 25.9 (5.9) 
WHS Tworoger et al. 2007 Case 63 55.7 (7.2) 25 65 75 24.5 (3.9) 
  Control 122 55.5 (7.0) 15 71 70 25.1 (4.4) 
Total  Case 1,270 45.5 (13.9) 9 40 42 26.3 (5.1) 
  Control 2,907 44.6 (13.8) 5 47 39 25.8 (4.6) 
1Among women with data: parity 2.2% missing; OC use 48% missing (excluding FMC: 0.3% missing) 
2Percentage presented for women with data: n=2,168 
 BMI = body mass index; CLUE = Washington County, MD Study ‘Give us a clue to cancer and heart disease’; EPIC = European Prospective Investigation into Cancer and Nutrition; FMC = Finish Maternity Cohort; NHS 
= Nurses’ Health Study; WHS = Women’s Health Study; 
 ≠      Data from Clue II have not been published.  




Table 2: Odds ratios (95% CI) for tertiles and doubling of  
IGF-I and EOC risk overall and IGF-I doubling and EOC risk by  
tumor characteristics, menopausal status at blood donation and  




 Sets OR (95%CI) ptrend2 
Overall EOC    
Tertile 1    460 ref  
Tertile 2   441 0.93 (0.78 - 1.09)  
Tertile 3   369 0.75 (0.62 - 0.90) <0.012 
Doubling 1,270 0.82 (0.72 - 0.93) <0.01 
ORs for Doubling   
Histology   
Serous 630 0.89 (0.74 - 1.06) 0.19 
Endometriod 163 0.82 (0.56 - 1.20) 0.32 
Mucinous 186 0.81 (0.58 - 1.12) 0.21 
Clear Cell 57 0.50 (0.26 - 0.99) 0.04 
phet3   0.62 
Grade  
Low grade 49 1.25 (0.52 - 3.03) 0.62 
High grade 377 0.82 (0.63 - 1.07) 0.15 
phet3   0.43 
Dualistic Pathway4    
Type I 277 0.78 (0.59 - 1.03) 0.08 
Type II 284 0.87 (0.64 - 1.18) 0.35 
phet3   0.67 
Disease Stage    
Local  246 0.79 (0.59 - 1.06) 0.12 
Regional/metastatic 802 0.84 (0.71 - 0.98) 0.03 
phet3   0.79 
Menopausal Status at Blood Collection  
Premenopausal 738 0.84 (0.71 - 0.98) 0.03 
Postmenopausal 532 0.80 (0.65 - 0.99) 0.04 
phet3   0.79 
Age at Diagnosis  
Age < 55  665 0.80 (0.67 - 0.94) 0.01 
Age ≥ 55 605 0.86 (0.71 - 1.04) 0.12 
phet3   0.60 
1ORs from conditional logistic regression models adjusted for OC use 
(never/ever/missing) and parity (never/ever/missing). Tertiles cutpoints based on all 
study controls using IGF-I concentrations standardized to mean=0 ng/mL: T1: ≤ -
0.20, T2: > -0.20 to 0.26; T3: >0.26. 
2The p value for trend across tertiles is based on a continuous probit score 
(generating a rank for each person in each cohort by hormone level); ptrend for 
doubling of hormone concentrations was estimated on log2 scale.  
3P for heterogeneity from likelihood ratio test comparing a model allowing the 
association to vary by subtype versus one assuming the same association across 
subtype using polytomous conditional logistic regression;  for age at 
diagnosis, Wald p-value from interaction term 
4 Type I: Low-grade serous and endometrioid, and all mucinous and clear cell cases; 




Figure 1. OR (95% CI) for the association between circulating IGF-I and overall EOC risk 
for each of the cohorts included in the pooled re-analysis, and results from meta-analysis: the 
Ovarian Cancer Cohort Consortium (OC3)  
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Table S1: Basic information on the participating cohort studies for the pooled analysis within the OC3 consortium 
Cohort (cases)     Population        Recruitment         
                                                            period 
  Fasting  
  status 
Storage   Matching criteria 
    Controls  
per case 
Age at blood 
donation 












-70°C 1:2 ± 1 years ± 14 days ± 1 day Menopausal 
status at blood 
collection 
Current OC / HRT 
use 








1992-2000 Matched -196°C1 1:2 ± 6 months No (incidence 
density 
sampling) 
5 phases Menopausal 
status at blood 
collection  
Recruitment 
center, Time of the 
day of blood 
collection,  





-25°C 1:3 ± 6 months ± 3 months Not 
available 
Not available Parity (1,2,>2), 
parity at diagnosis 
(1,2,>2) 
NHS and II2 
(138) 
Registered 
nurses in the 
USA 







Time of day, use 
of postmenopausal 
hormones at blood 
collection  















randomization (± 6 
months) 
CLUE II = Campaign against Cancer and Heart Disease study. EPIC= European Prospective Investigation into Cancer and Nutrition. FMC= Finnish Maternity Cohort. NHS= Nurses’ Health Study. NYU WHS = New York 
University Women’s Health Study. 1Most samples were stored in liquid nitrogen at -196°C, apart from Denmark and Sweden were samples were stored locally at -150°C and -70°C. 2NHS phase 1 (1999-2003 follow-up cycles 
and phase 2 (2005-09 follow-up cycles).     3Patients were asked to provide follicular sample at 3-5 days and luteal sample at 7-9 days before anticipated start of the next cycle. 4 RCT = Randomised Controlled Trial; RCT only 




Table S2: Laboratory assays and Intra- and Interbatch CV’s for IGF-I measurements in the participating cohorts 






   CLUE II Plasma ELISA1 2.8 3.2 
   EPIC phase 1 Serum 
 
ELISA1 2.5 12.2 
   EPIC phase 2 ELISA2 9.4 8.9 
   FMC Serum Chemiluminescent immunoradiometric3 14.6 13.2 
   WHS* Plasma ELISA range* 
from 
2 to 10 
- 
   NHS* Plasma ELISA - 
   NHS II* Plasma ELISA - 
1Enzyme-linked immunosorbent assay (ELISA); DSL, Webster, Texas, USA; 2Immunodiagnostics Systems, Germany. 3Quantified on the Immulite 2000 Siemens analyzer, a solid-phase enzyme-labeled 
chemiluminescent immunometric assay, using reagents from Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA 




Table S3. Tumor characteristics by cohort in pooled analysis of prospective data on IGF-I and EOC risk: OC3  
 Clue II EPIC FMC NHS NHS II WHS Total 
References ≠ Ose et al. 2014 Schock et al. 
2014 
Tworoger et al. 
2008 
Tworoger et al. 
2008 
Tworoger et al. 
2008 
 
No 46 450 575 121 15 63 1,270 
Age at dx, yrs 1 67.4 (13.0) 62.5 (8.9) 44.7 (8.1) 65.0 (7.3) 48.8 (3.8) 60.1 (8.0) 54.6 (12.5) 
Lag time, yrs 1 6.6 (3.0) 6.6 (3.6) 12.3 (6.8) 7.1 (4.0) 2.7 (1.9) 4.3 (2.6) 9.1 (6.1) 
Histology        
Serous 19 (41%) 237 (53%) 263 (46%) 64 (53%) 5 (33%) 42 (67%) 630 (50%) 
Endometrioid 5 (11%) 45 (10%) 92 (16%) 12 (10%) 4 (27%) 5 (8%) 163 (13%) 
Mucinous 2 (4%) 30 (7%) 142 (25%) 9 (7%) 1 (7%) 2 (3%) 186 (15%) 
Clear cell 2 (4%) 25 (5%) 23 (4%) 5 (4%) 2 (13%) - 57 (4%) 
Others 18 (39%) 113 (25%) 55 (10%) 31 (26%) 3 (20%) 14 (22%) 234 (18%) 
Grade 2        
Low grade 1 (4%) 31 (12%) - 11 (12%) 3 (25%) 3 (7%) 49 (12%) 
High grade 24 (96%) 220 (88%) - 82 (88%) 9 (75%) 42 (93%) 377 (88%) 
Stage 2        
Low stage 3 (9%) 57 (14%) 150 (31%) 29 (24%) 7 (47%) - 246 (24%) 
High stage 29 (91%) 340 (86%) 331 (69%) 90 (76%) 8 (53%) - 798 (76%) 
Type 2        
Type I 5 (24%) 76 (32%) 165 (100%) 21 (24%) 6 (55%) 4 (11%) 277 (49%) 
Type II 16 (76%) 163 (68%) - 68 (74%) 5 (45%) 32 (89%) 284 (51%) 
1presented as mean (±std)  
2Among cases with data. Grade missing for 66%, stage missing for 18%, Type I/II missing for 56% 
≠      Data from Clue II have not been previously published.  
 
 
